Epigral reported 16% revenue growth and 10% EBITDA growth in the first quarter, while announcing a ₹600 crore entry into epoxy resin and formulations as part of its specialty chemicals expansion strategy. The move adds a new product line to a company already focused on specialty chemicals, and the scale of the planned investment suggests Epigral is broadening its manufacturing base beyond its current operations. For readers tracking the sector, the announcement also shows how chemical companies are using quarterly results to signal capital deployment plans alongside ongoing growth in sales and operating performance.